Supplemental Table 1. LOGISTIC REGRESSION MODEL COMPARISON OF PREDICTIVE FACTORS AMONG PATIENTS WITH GRADE 1 OR 2/GRADE 3 OR 4 DERMATITIS
Characteristics
Proportion Logistic Regression Model (Grade 3–4 vs. Grade 1–2)
Grade 1–2 Grade 3–4 Unadjusted Model Adjusted Model
n (%) n (%) OR (95% Cl) P OR (95% Cl) P
Patients 493 (57.06) 247 (28.59)
Sex
Male 369 (74.85) 197 (79.76) 1 .138 1 .879
Female 124 (25.15) 50 (20.24) 0.755 (0.521–1.095) 0.965 (0.612–1.523)
Age, y
≤60 423 (85.8) 203 (82.19) 1 .200 1 .253
>60 70 (14.2) 44 (17.81) 1.31 (0.867–1.979) 1.354 (0.805–2.278)
Payment type
Insurance 438 (88.84) 224 (90.69) 1 1
Self-pay 54 (10.95) 22 (8.91) 0.797 (0.473–1.342) .393 0.798 (0.432–1.475) .472
Relationship status
Married 477 (96.75) 241 (97.57) 1 1
Single 16 (3.25) 6 (2.43) 0.742 (0.287–1.921) .539 0.969 (0.335–2.804) .954
Birthplace
Local 410 (83.16) 211 (85.43) 1 1
Not local 83 (16.84) 36 (14.57) 0.843 (0.551–1.289) .430 0.892 (0.542–1.469) .654
Smoking status
Current smoker 85 (17.24) 75 (30.36) 2.245 (1.559–3.232)* <.001 1.748 (1.011–3.022)* .046
Past smoker 34 (6.9) 25 (10.12) 1.871 (1.079–3.244)* .026 2.143 (1.039–4.417)* .039
Never smoked 374 (75.86) 147 (59.51) 1 1
Drinking status
Current drinker 68 (13.79) 52 (21.05) 1.666 (1.117–2.484)* .012 1.01 (0.561–1.818) .974
Past drinker 9 (1.83) 4 (1.62) 0.968 (0.294–3.183) .957 0.307 (0.069–1.361) .120
Never drank 416 (84.38) 191 (77.33) 1 1
Body mass index, kg/m2
<18.5 116 (23.53) 53 (21.46) 0.888 (0.6–1.313) .551 1.039 (0.666–1.623) .866
18.5–23.9 237 (48.07) 122 (49.39) 1 1
>23.9 140 (28.4) 72 (29.15) 0.999 (0.698–1.43) .996 0.924 (0.606–1.41) .715
Comorbidity 102 (20.69) 60 (24.29) 1.23 (0.855–1.769) .264
Hypertension 44 (8.92) 25 (10.12) 1.149 (0.686–1.926) .598 0.844 (0.43–1.657) .622
Diabetes 19 (3.85) 14 (5.67) 1.499 (0.739–3.043) .262 1.104 (0.456–2.675) .826
Coronary heart disease 4 (0.81) 3 (1.21) 1.503 (0.334–6.769) .596 1.436 (0.222–9.291) .704
Cerebrovascular disease 1 (0.2) 2 (0.81) 4.007 (0.362–44.363) .258 1.759 (0.098–31.716) .702
Hepatitis 48 (9.74) 24 (9.72) 0.998 (0.596–1.671) .993 0.884 (0.482–1.62) .689
Tuberculosis 4 (0.81) 2 (0.81) 0.998 (0.182–5.486) .998 1.397 (0.187–10.438) .744
Hyperthyroidism 3 (0.61) 1 (0.4) 0.664 (0.069–6.417) .724 1.617 (0.148–17.667) .694
Karnofsky Performance Scale score
70 8 (1.62) 1 (0.4) 0.294 (0.034–2.537) .266 0.229 (0.019–2.776) .247
80 44 (8.92) 36 (14.57) 1.925 (0.939–3.949) .074 1.35 (0.589–3.096) .478
90 247 (50.1) 97 (39.27) 0.924 (0.5–1.708) .801 0.699 (0.353–1.384) .304
100 40 (8.11) 17 (6.88) 1 1
(continues)
Supplemental Table 1. LOGISTIC REGRESSION MODEL COMPARISON OF PREDICTIVE FACTORS AMONG PATIENTS WITH GRADE 1 OR 2/GRADE 3 OR 4 DERMATITIS , CONTINUED
Characteristics
Proportion Logistic Regression Model (Grade 3–4 vs. Grade 1–2)
Grade 1–2 Grade 3–4 Unadjusted Model Adjusted Model
n (%) n (%) OR (95% Cl) P OR (95% Cl) P
T stage
T1–2 192 (38.95) 86 (34.82) 1 1
T3–4 286 (58.01) 156 (63.16) 1.218 (0.884–1.678) .228 1.082 (0.681–1.72) .739
N stage
N0–1 157 (31.85) 57 (23.08) 1 1
N2–3 321 (65.11) 184 (74.49) 1.203 (0.685–2.116) .5201 1.386 (0.874–2.197) .0831
M stage
M0 445 (90.26) 217 (87.85) 1 1
M1 27 (5.48) 18 (7.29) 1.367 (0.737–2.537) .321 0.543 (0.088–3.353) .511
TNM stage
I 12 (2.43) 3 (1.21) 1 1
II 59 (11.97) 23 (9.31) 1.559 (0.403–6.038) .520 1.368 (0.281–6.658) .698
III 223 (45.23) 103 (41.7) 1.848 (0.51–6.688) .350 1.849 (0.373–9.165) .452
IVa 154 (31.24) 91 (36.84) 2.364 (0.65–8.599) .192 1.398 (0.26-7.512) .696
IVb-c 35 (7.1) 22 (8.91) 2.514 (0.637–9.924) .188 1.376 (0.165-11.508) .768
Radiotherapy
IMRT 283 (57.4) 150 (60.73) 1 1
3D-CRT 210 (42.6) 97 (39.27) 0.871 (0.638–1.19) .387 0.894 (0.485–1.647) .719
Fraction
Conventionally fractionated 254 (51.52) 118 (47.77) 1 1
Hyperfractionated 239 (48.48) 129 (52.23) 1.162 (0.856–1.577) .336 2.084 (1.145–3.794)* .016
IC 340 (68.97) 195 (78.95) 1.687 (1.177–2.42)* .005 0.829 (0.345–1.992) .675
IC cycles
1 155 (31.44) 59 (23.89) 1 1
2 132 (26.77) 85 (34.41) 1.691 (1.128–2.536)* .011 1.445 (0.891–2.345) .136
3 36 (7.3) 32 (12.96) 2.335 (1.33–4.099)* .003 2.322 (1.131–4.767)* .022
4 12 (2.43) 10 (4.05) 2.189 (0.898–5.337) .085 3.496 (0.916–13.342) .067
5 2 (0.41) 4 (1.62) 5.251 (0.937–29.425) .059 10.123 (1.248–82.086)* .030
6 3 (0.61) 5 (2.02) 4.376 (1.014–18.886)* .048 9.283 (1.459–59.072)* .018
IC drugs
Taxol 111 (22.52) 96 (38.87) 1 1
Docetaxel 183 (37.12) 83 (33.6) 0.524 (0.36–0.764)* .001 0.551 (0.349–0.868)* .010
Other 46 (9.33) 16 (6.48) 0.402 (0.214–0.756)* .005 0.518 (0.238–1.13) .098
IC platinum-based drugs
Cisplatin 245 (49.7) 159 (64.37) 1 1
Nedaplatin 90 (18.26) 32 (12.96) 0.548 (0.349–0.859)* .009 0.914 (0.501–1.67) .771
Other 5 (1.01) 4 (1.62) 1.233 (0.326–4.66) .758 0.615 (0.113–3.346) .574
IC 5-fluorouracil treated
5-fluorouracil 50 (10.14) 25 (10.12) 1 1
Other 290 (58.82) 170 (68.83) 1.172 (0.7–1.964) .546 1.498 (0.787–2.852) .219
Concurrent chemotherapy 441 (89.45) 212 (85.83) 0.714 (0.451–1.13) .150 0.558 (0.267–1.167) .121
(continues)
Supplemental Table 1. LOGISTIC REGRESSION MODEL COMPARISON OF PREDICTIVE FACTORS AMONG PATIENTS WITH GRADE 1 OR 2/GRADE 3 OR 4 DERMATITIS , CONTINUED
Characteristics
Proportion Logistic Regression Model (Grade 3–4 vs. Grade 1–2)
Grade 1–2 Grade 3–4 Unadjusted Model Adjusted Model
n (%) n (%) OR (95% Cl) P OR (95% Cl) P
CC cycles
1 100 (20.28) 33 (13.36) 1 1
2 233 (47.26) 109 (44.13) 1.417 (0.9–2.233) .133 1.833 (1.067–3.15)* .028
3 84 (17.04) 51 (20.65) 1.84 (1.088–3.11)* .023 2.152 (1.16–3.99)* .015
4 7 (1.42) 8 (3.24) 3.461 (1.166–10.275)* .025 1.858 (0.5–6.897) .355
5 8 (1.62) 3 (1.21) 1.136 (0.285–4.534) .857 0.364 (0.062–2.142) .264
6 4 (0.81) 5 (2.02) 3.785 (0.959–14.929) .057 2.708 (0.584–12.558) .203
7 3 (0.61) 2 (0.81) 2.02 (0.323–12.616) .452 1.235 (0.164–9.304) .838
8 1 (0.2) 1 (0.4) 3.03 (0.184–49.8) .438 5.455 (0.211-140.927) .307
CC platinum-based drugs
Cisplatin 210 (42.6) 136 (55.06) 1 1
Nedaplatin 211 (42.8) 51 (20.65) 0.373 (0.257–0.543)* <.001 0.451 (0.27–0.755)* .002
Other 20 (4.06) 25 (10.12) 1.93 (1.032–3.611)* .040 2.148 (1.022–4.514)* .044
Abbreviations: 3D-CRT, three-dimensional conformal radiotherapy; CC, concurrent chemotherapy; CI, confidence interval; IC, induction chemotherapy; IMRT, intensity-modulated radiation therapy; OR, odds ratio.
Note: ORs were calculated with the logistic regression model.Pvalues were calculated using the Wald test.
*Statistically significant result.